Investors question green tint of Teva's $5bn sustainability bond | Financial Times
Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Analysts Split Over Buffett's Backing of Teva Pharma | BioSpace
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Is Teva Pharmaceuticals a Brilliant Contrarian Pick? | The Motley Fool
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Teva Pharmaceuticals Industries Limited Investors of the Important November 23 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg
Teva Pharmaceutical: Investment Opportunity During Fed Rate Hike (NYSE:TEVA) | Seeking Alpha
Teva Stock Price Today | NYSE TEVA Live Ticker - Investing.com
DEFA14A
TEVA Pharmaceuticals sells Forest facility to private investor | WSET
Teva Pharmaceutical Industries — 9 Portfolio companies, 10 Investments, Team — Unicorn Nest
Teva to Launch New Growth Strategy at Investor Day | Business Wire
Teva: Great Investment With An Upside Even In Volatile Markets (NYSE:TEVA) | Seeking Alpha
Teva Stock Plunges On Flat Sales, Earnings Disappointment | Investor's Business Daily
Teva Stock Price Today | NYSE TEVA Live Ticker - Investing.com
Teva Pharmaceutical Initiated at Market Perform at BMO - TheStreet
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Jewish Values Investors JLens Target Israeli Company
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva CEO sees $2.5 billion in revenue for Austedo drug by 2027 | Reuters")
Teva CEO sees $2.5 billion in revenue for Austedo drug by 2027 | Reuters
TSYS Investor Relations (IR) by Total System Services, Inc.
Teva Pharmaceuticals will pay $420 million in a federal case
Teva to Launch New Growth Strategy at Investor Day
Teva Pharmaceuticals Portfolio Investments, Teva Pharmaceuticals Funds, Teva Pharmaceuticals Exits
